Jump to: navigation, search
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass392.494 g/mol

WikiDoc Resources for PAC-1


Most recent articles on PAC-1

Most cited articles on PAC-1

Review articles on PAC-1

Articles on PAC-1 in N Eng J Med, Lancet, BMJ


Powerpoint slides on PAC-1

Images of PAC-1

Photos of PAC-1

Podcasts & MP3s on PAC-1

Videos on PAC-1

Evidence Based Medicine

Cochrane Collaboration on PAC-1

Bandolier on PAC-1


Clinical Trials

Ongoing Trials on PAC-1 at Clinical

Trial results on PAC-1

Clinical Trials on PAC-1 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on PAC-1

NICE Guidance on PAC-1


FDA on PAC-1

CDC on PAC-1


Books on PAC-1


PAC-1 in the news

Be alerted to news on PAC-1

News trends on PAC-1


Blogs on PAC-1


Definitions of PAC-1

Patient Resources / Community

Patient resources on PAC-1

Discussion groups on PAC-1

Patient Handouts on PAC-1

Directions to Hospitals Treating PAC-1

Risk calculators and risk factors for PAC-1

Healthcare Provider Resources

Symptoms of PAC-1

Causes & Risk Factors for PAC-1

Diagnostic studies for PAC-1

Treatment of PAC-1

Continuing Medical Education (CME)

CME Programs on PAC-1


PAC-1 en Espanol

PAC-1 en Francais


PAC-1 in the Marketplace

Patents on PAC-1

Experimental / Informatics

List of terms related to PAC-1


PAC-1 (first procaspase activating compound) is a synthesized chemical compound that selectively induces apoptosis, or cell suicide, in cancerous cells. PAC-1 has shown good results in mouse models and is being further evaluated for use in humans.

Function and discovery

PAC-1 (pronounced "pack one") was discovered at the University of Illinois at Urbana-Champaign during a process that screened many chemicals for anti-tumor potential. This molecule, when delivered to cancer cells, signals the cells to self-destruct by activating an "executioner" protein, procaspase-3. Then, the activated executioner protein begins a cascade of events that destroys the machinery of the cell.

Uses of apoptosis in the body and its irregularities

This cascade of events is named apoptosis. Apoptosis is self-induced in cells to combat infections or DNA damage. For instance, when a cell in one's body is infected with a bacterium or virus, it will self-destruct to take away the resources needed by the virus to proliferate. Apoptosis is also found to help in embryo development (destroying the webbing in between an embryo's fingers to separate the fingers) and the regular replenishment of cells that are constantly being used up or destroyed (cells that line the intestinal tract), also called homeostasis.

A cell undergoing apoptosis. The dying cell blebs apart and sends signals to the phagocytes, which are part of the immune system, to engulf it.

The problem lies when one part of the apoptosis pathway is broken. Normally, the balance between cell division and apoptosis is rigorously regulated to keep the integrity of organs and tissues. Examples of broken apoptosis pathways occur in many cancers. If old lung cells cannot self-destruct to make room for new lung cells, a large mass of cells form and a tumor is made.

In many cases, the apoptotic pathway is disrupted because procaspase-3, the executioner protein, cannot be activated by the cell. This is analogous to an executioner who does not have orders to kill. Without the orders, the condemned will not die. The same analogy can be made with procaspase-3. Without activated procaspase-3, the apoptotic cascade will not occur and the cell will not destroy itself no matter how necessary it may be. PAC-1 acts a replacement order that works and bypasses the lawyers, court orders, and governor's calls. It will activate procaspase-3 indiscriminately.

How PAC-1 affects the apoptotic process

In cells, the executioner protein, caspase-3, is stored in its inactive form, procaspase-3. This way, the cell can quickly undergo apoptosis by activating the protein that is already there. This inactive form is called a zymogen. Procaspase-3 has a “safety catch” made of three aspartate amino acids. When this safety catch is released by the cell, procaspase-3 is activated to caspase-3, which starts the apoptotic cycle. PAC-1 cleaves these three amino acids to activate procaspase-3 into caspase-3. Also, caspase-3 further activates other molecules of procaspase-3 in the cell, causing an exponential increase in caspase-3 concentration. PAC-1 facilitates this process and causes the cell to undergo apoptosis quickly.[1]

Unfortunately, a selectivity problem arises because procaspase-3 is present in most cells of the body. However, it has been shown that in many cancers, including certain neuroblastomas, lymphomas, leukemias, melanomas, and liver cancers, procaspase-3 is present in higher concentrations.[1] For instance, lung cancer cells can have over 1000 times more procaspase-3 than normal cells.[1] Therefore, by controlling the dosage, one can achieve selectivity between normal and cancerous cells.

Further research and human application

Thus far, PAC-1 seems promising as a new anti-tumor drug. It is synthetically available and a few mouse trials have been performed with moderate success. PAC-1 is the first of many small molecules to directly influence the apoptotic machinery of cells.


  1. 1.0 1.1 1.2 Putt, K. et al. (2006). "Small-Molecule Activation of Procaspase-3 to Caspase-3 as a Personalized Anticancer Strategy" Nat Chem Biol 2: 543–50. PMID 16936720

External links